11% OF AMERICANS ARE ON A GLP-1

I've come across numbers like 8% by the end of 2025, 12% by the close of the first quarter, and more recently 15%.

My take is that, much like 83.25% of all statistics, these are pure fabrication. /j

It probably isn't too far off from what's actually happening, but there's surely a hefty amount of marketing spin aimed at growing the market.

One thing that's certain: Lindt has reported stronger dark chocolate sales in the U.S., and T-shirt manufacturers have already needed to rework their size-based production ratios.

TL;DR (Notebooklm)

A recent Gallup survey reveals that GLP-1 usage in the United States has reached a critical turning point, with 11% of Americans currently using these medications for weight management. Data shows that public awareness of these drugs has surged to 91%, while national obesity rates have begun to decline for the first time in years. The report highlights a significant trend where patients using compounded versions of the medication often report higher satisfaction levels regarding effectiveness compared to those on branded versions. Furthermore, upcoming expansions in Medicare and Medicaid coverage are expected to provide millions more with access, potentially stabilizing Type 2 diabetes rates through early intervention. Ultimately, the discussion emphasizes a shift toward personalized obesity medicine that integrates hormonal health and metabolic signaling to improve long-term patient outcomes.

Click to expand...
Click to expand...

10 key ideas (Notebooklm)

Drawing from the transcript of the Gallup 2024 report overview, here are 10 key takeaways on where GLP-1 usage stands right now:

  1. Explosive Growth in Usage: As of now, 11% of Americans (roughly 29 million people) are using GLP-1 medications for weight management — a huge jump from just 3% two years earlier.
  2. A Healthcare Tipping Point: These drugs have shifted from "early adoption" into mainstream medicine, with 15% of Americans (close to 40 million people) having tried a GLP-1 at some point.
  3. Historic Decline in Obesity Rates: For the first time in recent memory, U.S. obesity rates are going down, falling from 39.9% in 2022 to 36.4% — a trend that lines up directly with the surge in GLP-1 use.
  4. Stabilization of Type 2 Diabetes: Following years of consistent rises, diabetes rates are starting to flatten out. The data indicates that using these medications for weight management acts as a powerful prophylaxis, with one study finding that 94% of pre-diabetic patients did not go on to develop type 2 diabetes.
  5. Higher Satisfaction with Compounded Medications: Unexpectedly, patients on compounded GLP-1s rated their experience somewhat higher than those using brand-name drugs, with 39% of compounded users calling the treatment "extremely effective" versus 32% of branded users.
  6. Cost is the Primary Driver for Switching: Cost is still the top factor (66%) pushing patients to move from brand-name medications to compounded versions, especially after losing insurance coverage.
  7. Expanding Access Through Medicare and Medicaid: Millions more Americans are gaining access as Medicare widens coverage. What's more, by 2027, Medicaid programs will be able to purchase these drugs for $250, which is expected to set off a massive expansion in access for lower-income populations.
  8. Benefits Beyond Weight and Diabetes: GLP-1s are demonstrating considerable potential for treating related conditions, including obstructive sleep apnea, cardiovascular events, and non-alcoholic fatty liver disease.
  9. Universal Public Awareness: Awareness of these drugs has become almost universal, climbing from 80% in 2024 to 91% in 2026. The public conversation has moved on from "What is Ozempic?" to detailed questions about dosage, insurance, and long-term maintenance.
  10. The Importance of the Gut-Brain Axis: New research emphasizes that the nervous system is the "loudest signal" for metabolism. This points to the need for holistic care that tackles mental health, stress (cortisol), and individualized hormonal signaling rather than concentrating on just one pathway.
 
My guess would be that at least a quarter of the population has given a glp a try at some point.
 
The government bridge program brought millions on board by charging just $50 per month. Over the long haul, I doubt most of them will succeed, since these drugs aren't magic. A steady calorie deficit has to be built, and almost nobody realizes that or can pull it off. Shedding pounds still takes effort, and the majority won't bother changing their food choices or the amount of movement required.
 
Honestly, I'd guess the real share using it is bigger than that. A lot of folks feel too worried about judgment to admit to their loved ones that they take a glp1 😅
 
Yesterday I had lunch with several senior citizens. Half of the people there were taking GLPs. Before the subject was raised, just 1 person had disclosed it; everyone else admitted it once it came up. Among seniors, I figure eventually you reach a stage where you either say something or folks start murmuring about whatever terrible illness poor Edna has, and how much time she has left? 🙄 🤣
 
My guess is the true figure is bigger still. A lot of folks have no clear grasp of what they're taking—neither the generic nor brand names, nor what each is meant to do. Assuming the Gemini AI snippet below is accurate, the Gallup wording leaves out prescriptions written for diabetes, sleep apnea, and similar conditions. It could also miss those using Zepbound, generics, gray-market products, or retatrutide, since "such as" leaves an enormous amount open to interpretation.

  • Current Use: "Are you currently taking a GLP-1 prescription medication for weight loss, such as Ozempic, Wegovy, or Mounjaro?"
  • Lifetime Use: "Have you ever taken a GLP-1 prescription medication for weight loss at some point in the past?"
With 75% of US adults overweight or obese, 11% barely dents the bucket.
 
At least around where I live, it feels like a surprising number of folks still haven't caught wind of glp1s. Yesterday I spoke with a woman who mentioned she was on Jenny Craig, and I was completely stunned.
 
cldfront said:

At least around where I live, it feels like a surprising number of folks still haven't caught wind of glp1s. Yesterday I spoke with a woman who mentioned she was on Jenny Craig, and I was completely stunned.
Click to expand...
Haha, same here — someone in our circle is attending Weight Watchers meetings. Honestly, I had no idea that was still around.
 
Back
Top